1. Home
  2. SYBX

as 02-14-2025 9:58am EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Founded: N/A Country:
United States
United States
Employees: N/A City: WINCHESTER
Market Cap: 16.5M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 19.0K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.06 EPS Growth: N/A
52 Week Low/High: $1.22 - $2.16 Next Earning Date: 03-18-2025
Revenue: $2,777,000 Revenue Growth: 292.23%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

SYBX Daily Stock ML Predictions

Share on Social Networks: